Adherence to guidelines for respiratory syncytial virus immunoprophylaxis among infants with prematurity or chronic lung disease in three United States counties

Pediatr Infect Dis J. 2012 Nov;31(11):e229-31. doi: 10.1097/INF.0b013e318266bf89.

Abstract

Among infants with prematurity and/or chronic lung disease for whom respiratory syncytial virus immunoprophylaxis is recommended, we examined adherence in infants enrolled during healthcare visits for acute respiratory illness in 3 U.S. counties from 2001 to 2007. Immunoprophylaxis among infants who met national criteria for prophylaxis increased from 33% to 83% over the 6-year period; 17% (11/65) of infants who received immunoprophylaxis did not meet eligibility criteria.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antiviral Agents / therapeutic use
  • Chronic Disease
  • Humans
  • Infant
  • Infant, Newborn
  • Infant, Premature
  • Palivizumab
  • Practice Guidelines as Topic*
  • Respiratory Syncytial Virus Infections / drug therapy*
  • Time Factors
  • United States / epidemiology

Substances

  • Antibodies, Monoclonal, Humanized
  • Antiviral Agents
  • Palivizumab